21 February 2022
Diaceutics PLC
("Diaceutics" or the "Group" or the "Company")
Investor Presentation
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that CEO Peter Keeling and incoming CFO Nick Roberts will provide a live presentation relating to the Company's audited results for the year ended 31 December 2021 via the Investor Meet Company platform on 23 March 2022 at 1pm.
The presentation is open to all existing and potential shareholders and registration can be completed via the following link:
https://www.investormeetcompany.com/diaceutics-plc/register-investor.
Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.
Enquiries:
|
Diaceutics PLC Peter Keeling, Chief Executive Officer Stifel Nicolaus Europe Limited (Nomad & Broker) Ben Maddison Stewart Wallace Nick Adams Alma PR Caroline Forde Kieran Breheny Matthew Young |
Via Alma PR Tel: +44 (0)20 7710 7600 Tel: +44(0)20 3405 0205 diaceutics@almapr.co.uk |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.